A multidistrict antitrust litigation over the generic drugs Digoxin and Doxycycline has been significantly expanded to include numerous additional class action cases, all stemming from a wide-ranging federal probe that last year led two pharmaceutical executives to plead guilty to price-fixing charges.
The U.S. Judicial Panel on Multidistrict Litigation issued an order April 7 transferring several cases into the MDL that is pending in the U.S. District Court for the Eastern District of Pennsylvania with Judge Cynthia Rufe presiding.
